Xilio Therapeutics, Inc.
Xilio Therapeutics develops masked immuno-oncology therapies designed to activate selectively within the tumor microenvironment.
S-1Aug 28Latest SEC filing
Aug 12Latest story
August 2026
Sign inSign inXilio Therapeutics develops masked immuno-oncology therapies designed to activate selectively within the tumor microenvironment.